Geneva, Switzerland and Boston, MA – 31 May 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Month: May 2017
BioEquity Europe 2017 Conference Presentation
Q1 Report 2017
ObsEva Reports First Quarter 2017 Financial Results and Business Update
– Phase 3 Programs Underway in Uterine Fibroids and Assisted Reproduction Technology (ART) – Geneva, Switzerland and Boston, MA – May 18, 2017 – ObsEva SA (NASDAQ:…
ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022
– OBE022 is ObsEva’s potential first-in-class, oral and selective PGF2alpha receptor antagonist for the treatment of preterm labor – Geneva, Switzerland and Boston, MA – 18…
ObsEva SA to Attend BioEquity Europe 2017 in Paris
Geneva, Switzerland – 16 May 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017
Geneva, Switzerland and Boston, MA – May 11, 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics…